Sialorrhea Treatment Market Dynamics and Trends by 2030

[Research Report] The sialorrhea treatment market was valued at US$ 695.06 million in 2022 and is expected to reach US$ 1,042.37 million by 2030; it is estimated to record a CAGR of 5.2% from 2022 to 2030.

Market Insights and Analyst View:

The sialorrhea refers to excessive saliva production. When individuals have extensive posterior saliva leakage down their tracheas instead of being routinely swallowed, it is known as posterior sialorrhea. Patients affected by anterior sialorrhea experience excessive anterior or forward salivation, also known as drooling, onto their faces and clothing, which makes it difficult for them to maintain hygiene, take care of their skin, and interact with others. Aspiration, a long-term lung irritation caused by this, can occasionally lead to pneumonia.

Growth Drivers and Challenges:

Patients suffering from neurological illnesses have a higher chance of developing chronic sialorrhea. Sialorrhea is typically treated with symptoms resulting from long-term neurological disorders, which adds to the overall load on patients. Physical and psychological burdens of patients can negatively affect their quality of life. People who suffer from neurological conditions such as cerebral palsy, Parkinson's disease, stroke, or ALS are primarily affected by chronic sialorrhea. These disorders impair the muscular coordination necessary for swallowing and saliva management. Damage or degeneration of the nerves is a result of ALS or Parkinson's disease. The brain, salivary glands, and swallowing muscles are main signal transducers for these nerves. Signal disruption, poor swallowing, and salivary gland coordination result from the damage. According to a article published by the Journal of Clinical Neuroscience, in 2019, ~40% of children affected by cerebral palsy and 80% of adults suffering from Parkinson’s disease were having sialorrhea. The abovementioned factors drive the sialorrhea treatments market growth.

Adverse effects of pharmacologic therapy are irritation, restlessness, sedation, and delirium from the central effects of the drugs. Inhibition of gastrointestinal (GI) motility has resulted in worsening constipation in a population already plagued with such difficulties. Photophobia, urinary retention, and facial flushing are other side effects of the medications.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Sialorrhea Treatment Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope:

The sialorrhea treatment market is bifurcated on the basis of medical therapy and end user. By medical treatment, the market is segmented into pharmacologic therapy, radiotherapy, and others. The sialorrhea treatment market, by end user, is segmented into hospitals, specialty clinics, homecare settings, and others. The sialorrhea treatment market, based on geography, is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America)

Segmental Analysis:

Based on medical therapy, the sialorrhea treatment market is segmented into pharmacologic therapy, radiotherapy, and others. In 2022, the pharmacologic therapy segment held the largest market share. Also, the segment is expected to record the highest CAGR during 2022–2030. Vaccines provide active acquired immunity against particular infectious diseases. In multiple independent clinical trials, pharmacological treatments such as benztropine, glycopyrrolate, scopolamine, and botulinum toxins have been demonstrated to be effective in managing sialorrhea. Medications are delivered orally or parenterally. Botulinum toxin is injected into the salivary gland guided by anatomical external palpation or ultrasonography.

The sialorrhea treatment market, by end user, is segmented into hospitals, specialty clinics, homecare settings, and others. The hospitals segment held the largest market share in 2022 and is anticipated to record the highest CAGR during 2022–2030. The treatment for sialorrhea is done in hospitals through appropriate treatment and motor therapy, with the help of highly experienced interdisciplinary medical specialists, including physiotherapists and neurology specialists.

Regional Analysis:

Based on region, the sialorrhea treatment market is categorized into five key regions—North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. The market in North America has been analyzed with a prime focus on three major countries—the US, Canada, and Mexico. Asia Pacific is expected to record the highest CAGR in the sialorrhea treatment market during 2022–2030. Growing government initiatives to increase awareness regarding this condition, increasing research and development activities in the region, growing market players' shifts toward providing better treatment options are among the prominent factors propelling the sialorrhea treatment market growth.

Sialorrhea Treatment Market Opportunity:

Improvised Curative Gene Therapy for Sialorrhea Treatment to Offer Lucrative Opportunities for Sialorrhea Treatment Market During Forecast Period

According to NIH, an experimental trial showed that gene therapy can be executed safely in the human salivary gland. The gene helps salivary gland cells secrete saliva into the mouth. Ad5-mediated transfer of the N-myc downstream-regulated gene 2 (NDRG2) to correct the salivary hypofunction. Also, use of NDRG2 gene transfer may be useful clinically for postmenopausal women who suffer from salivary hypofunction and do not want to risk the side effects of estrogen supplementation therapy. Therefore, the abovementioned factors are expected to provide opportunities for the sialorrhea treatment market in the coming years.  

Sialorrhea Treatment Market Regional Insights

The regional trends and factors influencing the Sialorrhea Treatment Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Sialorrhea Treatment Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Sialorrhea Treatment Market Report Scope

Sialorrhea Treatment Market Players Density: Understanding Its Impact on Business Dynamics

The Sialorrhea Treatment Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Competitive Landscape and Key Companies:

Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GSK Plc., Bayer AG, and Sun Pharmaceutical Industries Ltd. are among the prominent players operating in the global sialorrhea treatment market. These companies focus on the development of new technologies, advancements in existing products, and expansion of geographic footprint to meet the growing consumer demand worldwide and expand their product range in specialty portfolios. Companies operating in the global sialorrhea treatment market are implementing various inorganic and organic strategies. A few of them are mentioned below:

• In August 2021, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, was granted the use of XEOMIN for the symptomatic treatment of chronic sialorrhea in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg due to neurodevelopmental disorders/neurological on EU level. The US Food and Drug Administration approved it in December 2020, and the Russian Federal Service for Surveillance in Healthcare August 2021.
• In February 2023, Proveca Pharma Ltd, a pharmaceutical company that specializes in medicines for children, provided Sialanar (glycopyrronium bromide) to children suffering from severe sialorrhea due to chronic neurological disorders in France.